BioMarin appoints Timothy Walbert to board, expanding size to 12 members

BIOMARIN PHARMACEUTICAL INC

Board increased from 11 to 12 members; Walbert appointed effective February 24, 2025.
Walbert receives standard independent director compensation including pro rata RSU grant (annual award $400,000).
No committee assignments at this time; standard indemnification agreement to be entered into.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Timothy P. Walbert

Director

BMRN · BIOMARIN PHARMACEUTICAL INC

Effective: 2025-02-24
Filed: February 24, 2025, 6:59 PM ET

the Board of Directors (the “Board”) of BioMarin Pharmaceutical Inc. (the “Company”) increased the size of the Board from eleven to twelve members and appointed Timothy P. Walbert to the Board, to be effective February 24, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Timothy P. Walbert was appointed as Director at BIOMARIN PHARMACEUTICAL INC.

Action: appointed
Role: Director

Exact text from the filing

the Board of Directors (the “Board”) of BioMarin Pharmaceutical Inc. (the “Company”) increased the size of the Board from eleven to twelve members and appointed Timothy P. Walbert to the Board, to be effective February 24, 2025.

View on SEC.gov

BIOMARIN PHARMACEUTICAL INC filing history →

Source: SEC EDGAR

accession 0001193125-25-033463

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.